GH-21

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameGH-21
Drug Alias NameGH-21HBI-2376GH 21005
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSrc homology phosphotyrosyl phosphatase 2 inhibitors
TargetsSrc homology phosphotyrosyl phosphatase 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Genhouse Bio Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHuya Bioscience International LlcHuyabio International LLCSuzhou Genhouse Bio Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A